文献速递遗传性与小管间质肾病血液净化与透析肾移植

全球原发性高草酸尿症管理可及性调查

Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究通过国际横断面问卷收集57国136份回复,评估原发性高草酸尿症(PH)诊疗可及性。结果显示遗传检测可及性82%,尿草酸测定97%,但低高收入国家间多项诊断项目差异显著;保守治疗全球可及性高,腹膜透析及肝肾移植可及性差异显著;RNAi药物lumasiran仅高收入和中收入国家可及,总体53%。

要点

  • 全球PH诊断可及性不均衡,遗传检测82%,尿草酸97%。
  • RNAi药物lumasiran仅高收入和中收入国家可及,总体53%。

核心结论

  • 全球PH患者管理可及性存在差异,低资源地区受影响更甚。
  • 即使在高收入国家,RNAi治疗也并非总能获得。

研究设计与样本

  • 国际横断面问卷研究,收集2023年3月至2024年4月间57国136份医疗提供者回复。
  • 采用混合随机效应模型进行荟萃分析并调整亚组差异。

主要发现

  • 遗传分析诊断可及性82%(CI 77%-91%),尿草酸测定97%(93%-100%)。
  • RNAi药物lumasiran总体可及性53%(40%-66%),高收入国家78%,中收入国家56%。

临床怎么用

  • 应关注低资源地区PH诊断与治疗的可及性差距。
  • 高收入国家也需评估RNAi治疗的实际可及性。
  • 调查结果可为改善全球PH患者结局的倡议提供支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary hyperoxaluria (PH) is a rare disorder with significant morbidity and mortality if left untreated. Given the rarity, global inequities in diagnostics and treatment are expected. Recently introduced RNA interference therapeutics (RNAi) have dramatically changed the outcome for PH patients, potentially disproportionately affecting low-resource regions. Understanding these disparities is crucial for implementing measures to ensure equitable healthcare access for PH patients worldwide. This study aims to evaluate the current global health situation for PH patients upon the introduction of targeted therapeutics. METHODS: An international cross-sectional questionnaire study was conducted among healthcare providers involved in PH care. Responses were gathered between March 2023 and April 2024 and distributed by e-mail via various international nephrology networks. Meta-analysis (mixed random effects model with inverse-variance weighting) was used to analyze data and adjust for subgroup differences. RESULTS: We gathered 136 responses from 57 countries, representing all World Bank regions. Overall access to genetic analysis diagnostics was 82% (confidence interval 77%-91%) and to urinary oxalate measurement 97% (93%-100%). Significant differences (P < .05) between low- and high-income countries were found for most diagnostics including genetic testing, plasma oxalate, plasma and urinary glycolate. Conservative therapies (e.g. pyridoxine and alkalinizing agents) were highly available globally (98% and 95%), but significant differences in access to peritoneal dialysis, and kidney and liver transplantation were reported (P < .05). Access to the RNAi therapeutic lumasiran was limited to high- and middle-income countries, with 53% (40%-66%) of all countries having access (78% high-income versus 56% middle-income). Even in high-income countries, RNAi was not always accessible. CONCLUSIONS: We found global disparities in access to optimal management of PH patients, disproportionately affecting low-income countries, but even existing between high-income countries. These results may provide support for initiatives to improve the outcome of PH patients worldwide in an era of new targeted therapeutic treatments.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Deesker LJ, Oubram L, Almardini R, et al. Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN. Nephrol Dial Transplant. 2025. PMID: 39984743. doi:10.1093/ndt/gfaf035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。